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Background: Miliary brain metastases are a rare condition but associated with an exceedingly poor prognosis. We
present the case of a patient suffering from malignant melanoma with an acute progressively worsening of
neurological symptoms up to the loss of consciousness. The magnetic resonance imaging (MRI) demonstrated a
new onset of disseminated, miliary spread of central nervous system metastases from a malignant melanoma
within 4 days.
Case presentation: We report on a 57-year-old woman suffering from metastatic malignant melanoma positive for
BRAF-V600E mutation who developed an acute onset of neurological symptoms. The patient received vemurafenib and
dacarbacin as chemotherapeutic regime for treatment of malignant melanoma. After admission to our hospital due to
progressive disturbance of memory and speech difficulty a magnetic resonance tomography (MRI) was performed. This
showed no evidence of cerebral tumour manifestation. The symptoms progressed until a loss of consciousness occurred
on day five after admission and the patient was admitted to our intensive care unit for orotracheal intubation. No
evidence for infectious, metabolic or autoimmune cerebral disorders was found. Due to the inexplicable acute
worsening of the neurological symptoms a second MRI was performed on day five. This revealed a new onset of
innumerable contrast-enhancing miliary lesions, especially in the grey matter which was proven as metastases
from malignant melanoma on histopathology.
Conclusion: This case describes an unique hyperacute onset of tumour progression correlating with an acute
deterioration of neurological symptoms in a patient suffering from miliary brain metastasis from BRAF positive
malignant melanoma.
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The incidence of malignant melanoma is increasing
during the last decades, especially in the Caucasian
population [1]. Cutaneous Melanoma reflects the skin
cancer with the highest mortality [2]. Malignant melan-
oma commonly metastasizes to the central nervous sys-
tem (CNS) [3] and cerebral metastases from malignant* Correspondence: florian.reiter@med.uni-muenchen.de
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creativecommons.org/publicdomain/zero/1.0/melanoma are known to have a variety of appearances
and cerebral locations [4]. In general the brain is a fre-
quent site of metastasis in patients suffering from dis-
seminated malignant melanoma [5] however only 5 %
of patients with multiple melanoma metastases have
more than five intracerebral metastatic lesions [3], and
especially a miliary pattern seems to be a rarity [3, 6].
A miliary pattern of brain metastases refers to a wide-
spread dissemination of innumerable small punctate le-
sions. This condition indicates an exceedingly poor
prognosis [3].icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 T1-weighted sequence of MRI. The axial T1-weighted sequence
after intravenous administration of a Gadolinium-based contrast
medium demonstrates a military pattern of innumerable small
contrast-enhancing lesions with a predilection of the grey matter
including the cerebral cortex, basal ganglia and thalami
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with an acute progressively worsening of neurological
symptoms up to the loss of consciousness. The magnetic
resonance imaging (MRI) demonstrated a new onset of
disseminated, miliary spread of CNS metastases from a
malignant melanoma within 4 days. The diagnosis was
proven by histopathology.
Case presentation
A 57-year old woman was admitted to our hospital with
a 3-day history of progressive disturbance of memory
and speech difficulty. The patient was suffering from
known pulmonary, hepatic, subcutaneous and bone
metastases 21 months after the initial diagnosis and ex-
cision of a malignant melanoma on the helix of the
right auricle (Clark Level 2, BRAF status: V600E posi-
tive). Metastatic disease was histologically confirmed in
a cutaneous biopsy at this point. The patient had been
treated with a chemotherapeutic regimen with vemura-
fenib 960 mg and dacarbacin 1000 mg/m2 for 2 months
prior to admission.
Six months after the initial diagnosis of malignant mel-
anoma, the patient had additionally been diagnosed with a
neuroendocrine tumour (NET) of the terminal ileum with
a Ki-67 index of 8–10 %. The patient subsequently under-
went a laparoscopic resection of the ileocecal region.
One day after admission, the patient had signs of an
expressive aphasia, paraphasic errors, word substitution
errors, and impaired repetition. She had difficulties in
understanding conversation, but she was able to follow
simple commands, recall was poor. An impaired coord-
ination with tremor was present. The patient was ori-
ented regarding person but only partially regarding
time and situation. No cranial nerve dysfunction, par-
eses or pyramidal tract signs were present. Deep tendon
reflexes were adequate on both sides. Sensibility was
not impaired.
One day after admission, a gadolinium enhanced MRI
of the brain was performed. Neither cerebral metastases
nor signs of meningeal carcinomatosis were noted. A lum-
bar puncture was subsequently performed. Cerebrospinal
fluid (CSF) analysis showed no detectable leukocytes, an
elevated total protein content (54 mg/dl) and a normal
CSF glucose (69 mg/dl). Oligoclonal IgG bands were nega-
tive in serum and CSF. No malignant cells were detected
in the CSF by microscopy.
An antiepileptic therapy with benzodiazepines (loraze-
pam) and levetiracetam was initiated, which did not lead
to an improvement of the clinical situation. An EEG did
not reveal signs of nonconvulsive status epilepticus.
Subsequently, a contrast enhanced CT scan of the neu-
rocranium was obtained 2 days after admission. This was
essentially normal without signs of haemorrhage, ische-
mia, metastases or elevated intracranial pressure. Duringthe following 4 days, the patient´s level of consciousness
progressively decreased and the patient became somno-
lent. At this point the patient was aphasic with completely
absent speech production. The patient was unable to fol-
low instructions. The Babinski sign was absent and deep
tendon reflexes were unremarkable. Metabolic or endo-
crinological causes for the patient´s somnolence were
excluded.
The patient was admitted to our intensive care unit
for orotracheal intubation on day 5 after admission due
to a Glasgow Coma Scale score of 7.
On day 5 after admission, a further gadolinium en-
hanced MRI of the brain was performed, which now
demonstrated innumerable contrast-enhancing miliary
lesions, especially in the grey matter of the cerebrum,
cerebellum, putamen, caudate nucleus and thalamus ac-
companied by low grade edema (Figs. 1 and 2). Repeat
review of the initial MRI again confirmed the absence of
these lesions at that time.
A repeated lumbar puncture again showed no leuko-
cytes in the CSF, an elevated total protein content (73 mg/
dl), a normal CSF-serum glucose ratio (86/165 mg/dl) and
again, oligoclonal IgG bands were negative in serum and
CSF. No malignant cells were detected in the CSF by
microscopy.
Due to the uncommon presentation of the acute-
onset miliary pattern in the cerebral grey matter, brain
Fig. 2 FLAIR sequence of MRI. The axial FLAIR sequence shows
multiple small areas of signal hyperintensities in the grey matter and
in the leptomeninges
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performed to exclude infectious and autoimmune
causes and to potentially differentiate the type of me-
tastases. Intraoperative inspection demonstrated dark
spotted lesions disseminated over the meninges and the
cerebrum. Histologic examination confirmed cerebralFig. 3 H&E stain. H&E stain of a biopsy from a suspect cortical lesion, show
cells bear conspicuous brownish pigmentmetastases of a malignant melanoma (Figs. 3 and 4).
The molecular examination of the brain metastasis con-
firmed BRAF mutation also in this compartment.
Due to the rapidly deteriorating condition and a dis-
mal prognosis, after interdisciplinary discussion with on-
cologists, dermatologists and radiation oncologists it was
decided to extubate the spontaneously breathing patient.
She received palliative care and deceased 5 days after the
biopsy without regaining consciousness.
Our patient experienced a very acute onset of clinically
relevant cerebral metastases within 4 days from the ini-
tial MRI of the brain, which had not shown evidence of
cerebral metastases. The demonstration of miliary me-
tastases in the second MRI of the brain was accompan-
ied by an exacerbation of neurological symptoms. The
acute deterioration of the disease process occurred
23 months after the initial diagnosis of malignant melan-
oma under active treatment with vemurafenib 960 mg
and dacarbacin 1000 mg/m2 for the past two months.
Vemurafenib is an oral tyrosine kinase inhibitor tar-
geting the oncogenic BRAF V600 protein kinase. It is
approved for the treatment of BRAF V600 mutation-
positive unresectable or metastatic melanoma [7]. Des-
pite improved response rates and increased survival,
malignant melanoma cells can acquire resistance to B-
RAF (V600E) by receptor tyrosine kinase-mediated ac-
tivation of alternative pathways [8]. In our case, the
rapid progression under targeted therapy for metastatic
melanoma is suggestive of an accelerated alternative path-
way activation and massive cerebral spread of the disease
being associated with severe worsening of neurologic
symptoms.ing invasion of the cortex with numerous tumour cells. Some tumour
Fig. 4 HMB-45 stain. HMB-45 stain of the biopsy sample shown in Fig. 4, showing positive immunoreactivity, verifying melanoma origin
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enhanced lesions [9]. In our case the patient showed a
normal cell count with no detectable leukocytes and a
normal glucose level within the CSF, which makes
CNS-listeriosis or bacterial meningitis unlikely. Crypto-
coccal disease was not detected in culture or antigen
test. Subdural and intracerebral swab was negative for
tuberculosis. No evidence for sarcoidosis was found
within the CSF or computed tomography of the thorax.
Due to an involvement of the grey matter an acute dis-
seminated encephalomyelitis can be excluded.
Bearing in mind the two different malignant entities in
the patient’s recent medical history, histological examin-
ation of the brain lesions was mandatory. NETs are the
origin of brain metastases in approximately 1.4 % of all
patients with cerebral metastases [10]. In patients with
NET, the incidence of brain metastases is estimated to
be up to 5 % [10]. Nevertheless, considering the fact that
most NET brain metastases have their origin in the
bronchopulmonary tract [10] and that the patients NET
of the ileum had a low Ki-67 index of 8–10 %, the
pretest-probability of a positive histology for NET espe-
cially in a patient with known melanoma metastases in
other parts of the body was low. Furthermore to our
best knowledge, as opposed to melanoma no case of
miliary brain metastases of a NET has been reported, so
far. Miliary brain metastases were reported several times
in patients suffering from lung cancer [11–13]. These
cases describe a slow onset of symptoms. Further, it is
reported that the cerebral lesions may not be detected in
computed tomography as seen in our case [13]. The
study by Rivas et al. described a rapidly onset of demen-
tia in a patient suffering from miliary brain metastasesof unknown primary adenocarcinoma [14]. This patient
deceased five and a half months after onset. Taken
together none of the mentioned studies showed a com-
parable hyperacute onset as seen in our case.
To our best knowledge no association between BRAF
mutations and multiple organ metastases were investi-
gated so far. The fact that the molecular analysis of the
brain metastases in our case confirmed a BRAF muta-
tion in this tissue raises the question whether there
could be also a correlation of the BRAF status with mul-
tiple and miliary organ metastasis as seen under EGRF
mutations in lung cancer [15–18].
Conclusion
Since there was no evidence of cerebral metastasis in the
initial MRI this report describes a very rapid tumour
progression in a patient suffering from malignant melan-
oma that timely correlated with an acute worsening of
consciousness and neurological symptoms.
Thereby it illustrates an unique time course of disease
progression in metastatic malignant melanoma.
Furthermore this case confirms the fact that malig-
nant melanoma has the potential to cause miliary brain
metastasis and raises the question if there might be an
association between BRAF status and miliary pattern of
metastasis.
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